Objective-The function of microRNAs is highly context and cell type dependent because of their highly dynamic expression pattern and the regulation of multiple mRNA targets. plays an important role in the innate immune response by regulating macrophage function; however, the effects of miR-155 in macrophages on atherosclerosis are controversial. We hypothesized that the stage-dependent target selection of miR-155 in macrophages determines its effects on atherosclerosis. Approach and Results-The expression of miR-155 increased in lesional macrophages of apolipoprotein E-deficient mice between 12 and 24 weeks of a high-cholesterol diet. Mir155 knockout in apolipoprotein E-deficient mice enhanced lesion formation, increased the lesional macrophage content, and promoted macrophage proliferation after 12 weeks of the high-cholesterol diet. In vitro, miR-155 inhibited macrophage proliferation by suppressing colony-stimulating factor-1 receptor, which was upregulated in lesional macrophages of Mir155 -/-apolipoprotein E-deficient mice. By contrast, Mir155 deficiency reduced necrotic core formation and the deposition of apoptotic cell debris, thereby preventing the progression of atherosclerosis between 12 and 24 weeks of the high-cholesterol diet. miR-155 inhibited efferocytosis in vitro by targeting B-cell leukemia/lymphoma 6 and thus activating RhoA (ras homolog gene family, member A). Accordingly, B-cell leukemia/lymphoma 6 was upregulated in lesional macrophages of Mir155 -/-apolipoprotein Edeficient mice after 24 weeks, but not after 12 weeks of the high-cholesterol diet.
A therosclerosis is a leading, but potentially preventable, cause of death and disability worldwide and results in devastating diseases, such as myocardial infarction because of coronary artery disease or stroke. 1 Modified forms of low-density lipoprotein (LDL), for example, resulting from oxidation, in the vessel wall induce the expression of adhesion molecules and chemokines in the endothelium, and this supports the adhesion and transmigration of circulating monocytes. 2 In the vessel wall, monocytes differentiate into macrophages, which transform into foam cells by intracellular cholesterol accumulation. In addition to monocyte recruitment, the proliferation of macrophages within plaques contributes to the lesional macrophage burden. 3 Colony-stimulating factor-1 (Csf1) secreted from endothelial cells promotes atherosclerosis by regulating the survival, proliferation, and differentiation of macrophages via the Csf1 receptor (Csf1r). [4] [5] [6] [7] The removal of apoptotic macrophages by efferocytosis induces an anti-inflammatory response, thereby promoting inflammation resolution and limiting the progression of atherosclerosis. 8, 9 However, a continuous supply of LDL to the intima and the limited reverse cholesterol transport capacity results in intracellular accumulation of cholesterol-ester in lipid droplets. The accumulation of free cholesterol in endoplasmic reticulum membranes increases macrophage apoptosis via activation of the unfolded protein response. 10 In addition to increased macrophage apoptosis, efferocytosis is defective in advanced atherosclerosis, partly owing to the deregulation of efferocytosis receptors. 11 Insufficient removal of apoptotic macrophages leads to secondary necrosis, which impairs inflammation resolution and promotes the formation of a highly thrombogenic necrotic core, the hallmark of vulnerable plaques.
The expression and targets of miRNAs are context and cell type dependent, which determines the biological function of miRNAs. 13 MiRNAs play important roles in the development of atherosclerosis.
14-17 Previously, we found that a hematopoietic microRNA-155 (Mir155) deficiency limits atherosclerosis in partially ligated carotid arteries of apolipoprotein E-deficient (Apoe -/-) mice by increasing the expression of B-cell leukemia/lymphoma 6 (Bcl6).
18 Mir155 knockout and inhibition by antagomirs in Apoe -/-mice reduce lesion formation after consuming a high-cholesterol diet (HCD). 19, 20 By contrast, hematopoietic Mir155 suppresses atherosclerosis in LDL receptor-deficient mice. 21 However, the cause of these contradictory findings is unclear.
Here, we demonstrate that miR-155 has opposite roles during early and advanced atherosclerosis. During the early stage of atherosclerosis, miR-155 suppressed lesion formation via reducing the lesional macrophage content by inhibiting Csf1r-mediated macrophage proliferation, whereas miR-155 promoted atherosclerosis by diminishing Bcl6-mediated phagocytosis of apoptotic cells during the advanced stage.
Materials and Methods
Materials and methods are available in the online-only Data Supplement.
Results

Role of miR-155 in Atherosclerosis at Different Stages
The expression level of miR-155 was upregulated in the aortas of Apoe -/-mice after 24 weeks as compared with 4 and 12 weeks of the HCD and tended to increase from 4 to 12 weeks ( Figure 1A) . Moreover, miR-155 expression was mainly detectable in Mac2 + mononuclear phagocytic cells after 12 and 24 weeks of the HCD as determined by combined in situ PCR and Mac2 immunostaining ( Figure 1A ). In vitro, treatment of bone marrow-derived macrophages (BMDMs) with oxidized LDL for 72 hours increased the expression level of miR-155 and cholesterol loading compared with 24 hours ( Figure I 
Role of Hematopoietic miR-155 in Atherosclerosis at the Early Stage
To study whether miR-155 derived from macrophages mediates the atheroprotective effects in early atherosclerosis, BM chimeric mice were generated. Increased lesion formation ( Figure 3A and 3B) and lesional macrophage accumulation ( Figure 3C ) was found in Mir155 
Apoe
-/-BM after the 12-week HCD feeding program. Similar to the results of the ubiquitous Mir155 knockout, the necrotic core area was not different between the 3 groups after 12 weeks of the HCD ( Figure 3A) .
Mechanism of the Opposite Roles of miR-155 During Atherogenesis
The accumulation of macrophages in early atherosclerotic lesions is dominated by their local proliferation and the formation of the necrotic core during lesion progression occurs because of an imbalance between macrophage apoptosis and efferocytosis. 8, 22 To determine the mechanisms of the opposite effects of miR-155 in atherosclerosis, combined Ki67/ Mac2 and terminal deoxynucleotidyl transferase dUTP nick end labeling/Mac2 immunostaining were performed to analyze macrophage proliferation and apoptosis, respectively. Previous study has shown that terminal deoxynucleotidyl transferase dUTP nick end labeling staining is only detected in apoptotic, but not necrotic macrophages, 23 suggesting that terminal deoxynucleotidyl transferase dUTP nick end labeling is a good indicator for apoptosis. Mir155 deficiency increased macrophage proliferation after 12 weeks but not after 24 weeks of the HCD ( Figure 4A ). By contrast, the apoptosis of lesional macrophages was not altered after 12 and 24 weeks in Mir155 
miR-155 Controls the Proliferation of Macrophages by Targeting Csf1r
Csf1r plays an important role in macrophage proliferation and is a target of miR-155 in myeloid cells. 24 Accordingly, the Csf1r mRNA expression was higher in the aortic roots of In vitro, Csf1r expression ( Figure 5D ) was increased in Mir155 -/-BMDMs compared with the control. In addition, Mir155 deficiency enhanced the proliferation rate of BMDMs in the presence of colony stimulating factor 1 (CSF1) contained in the conditional medium, but not in the absence of CSF1 ( Figure 5E ). Moreover, inhibition of Csf1r signaling using Ki20227 reduced the increased proliferation of Mir155 -/-BMDMs in the presence of CSF1 ( Figure 5E ). Enhanced Csf1r-mediated proliferation in Mir155 -/-BMDMs is probably the result of increased expression of type 1 scavenger receptor class A ( Figure 5F ), which is induced by Csf1 signaling and crucial for the local proliferation of lesional macrophages. 3, 25 These data indicate that miR-155 suppresses macrophage proliferation by targeting Csf1r.
miR-155 Regulates Macrophage Efferocytosis by Targeting Bcl6
We previously showed that increased expression of Bcl6 in Mir155 -/-macrophages reduces inflammatory responses and limits atherosclerosis. 18 However, the mechanism of the protective effect of Bcl6 is not completely understood. Notably, the Bcl6 mRNA expression level was increased in lesions of Mir155
Apoe
-/-mice compared with the control after 24 weeks, but not after 12 weeks of the HCD ( Figure 6A ). The stagedependent effect of Mir155 deletion on the expression of its targets in the lesions was only observed for Bcl6, and not for other targets, such as Socs1, PU.1, Rhoa, Ship1, and Hbp1 ( Figure  IV in the online-only Data Supplement). 16, 19, 20, 26, 27 Accordingly, the number of macrophages expressing Bcl6 protein was higher in lesions of Mir155
-/-mice after 24 weeks ( Figure 6B ). In vitro, the Bcl6 expression level was increased in Mir155 with an inhibitor of Bcl6 ( Figure 6D ), suggesting that the effect of miR-155 on macrophage efferocytosis is mediated by the targeting of Bcl6. Moreover, activation of the efferocytosis suppressor ras homolog gene family, member A (RhoA) was reduced in Mir155 -/-BMDMs, and this reduction was rescued by treatment with a Bcl6 inhibitor, indicating that the role of miR-155 in efferocytosis is mediated by Bcl6-RhoA axis ( Figure 6E ). However, the RhoA expression levels were not affected by Mir155 deficiency in either LPS/IFN-γ-stimulated macrophages or aortic roots, although the Rhoa mRNA level was increased in unstimulated Mir155 
Discussion
Our data demonstrate that miR-155 has a protective effect against early atherosclerosis but promotes advanced atherosclerosis. These opposite roles of miR-155 are attributable to the inhibition of macrophage proliferation by suppressing Csf1r in early and decreased efferocytosis by targeting Bcl6 in advanced atherosclerosis ( Figure 6F ).
The role of miR-155 in atherosclerosis has been studied previously by others and us [18] [19] [20] [21] ; however, the results are controversial. Knockout of Mir155 in BM cells reduces atherosclerosis induced by acutely disturbed flow in Apoe -/-mice by depressing Bcl6. 18 Moreover, Mir155 deficiency in BM cells reduced atherosclerotic lesion size, lipid deposition, and lesional macrophage content in aortic roots after a 16-week HCD feeding program in 16-week-old Apoe -/-mice. 19 These data indicate a proatherogenic role of macrophage-derived miR-155 at the advanced stage of atherosclerosis. Accordingly, we found that knockout of Mir155 reduces advanced lesion formation and increases Bcl6 expression after 24 weeks of the HCD. By contrast, LDL receptor-deficient mice repopulated with Mir155 -/-BM cells develop more atherosclerosis after 10 weeks of a HCD, indicating antiatherogenic effects of miR-155 expression in macrophages during early atherosclerosis. In line with this result, miR-155 limited lesion formation in Apoe -/-mice after 12 weeks of the HCD via reduced macrophage proliferation. Thus, miR-155 has opposite effects in early and advanced atherosclerosis and plays a crucial role in the progression of atherosclerosis.
Macrophage proliferation plays an important role in the development of atherosclerosis. The growth-promoting effect of Csf1 maintains tissue macrophages and contributes to macrophage proliferation under inflammatory conditions. 28, 29 Genetic deletion of Csf1 or its receptor Csf1r limits atherosclerosis, and blocking Csf1r with an antibody reduces early lesion formation, but has no effect on lesion progression. 7, 30 Thus, the effect of Csf1 on macrophage proliferation may be essential in the initiation of atherosclerosis. We found that miR-155 suppresses its target Csf1r in lesional macrophages from early and advanced atherosclerosis and inhibits macrophage proliferation by suppressing Csf1r in vitro. 24 However, the expression of Csf1 was greatly diminished during the progression of atherosclerosis. Therefore, the effect of miR-155 on Csf1r expression may only affect macrophage proliferation in early atherosclerosis because of the reduced availability of Csf1 in advanced atherosclerosis ( Figure 6F ). Csf1 upregulates the expression level of scavenger receptor class A, which mediates the proliferation In advanced atherosclerosis, increased cell apoptosis is accompanied by defective efferocytosis, thereby promoting the formation of a necrotic core and accelerating atherosclerosis. 8, 10, 11 We found that knockout of the miR-155 gene results in a smaller necrotic core size and reduced lesion formation during advanced atherosclerosis. Although miR-155 did not affect the apoptosis of lesional macrophages, the extracellular deposition of DNA from apoptotic cells in the necrotic core was substantially reduced in Mir155 -/-mice. These results indicate that miR-155 plays an important role in the progression of atherosclerosis by impairing efferocytosis. Unlike various other miR-155 targets, the expression of Bcl6 was selectively upregulated by Mir155 deficiency in advanced atherosclerosis. Notably, Bcl6 can inhibit the activity of RhoA, which negatively regulates efferocytosis by activating ROCK1. [32] [33] [34] Moreover, Bcl6 deficiency in macrophages increases lesion formation and the necrotic core area in Apoe -/-mice. 35 Hence, miR-155 may impair efferocytosis by targeting Bcl6. Accordingly, we found that suppression of Bcl6 by miR-155 increases RhoA activity and inhibits efferocytosis. This effect of miR-155 on RhoA activity is in contrast to previous findings that RhoA is a target of miR-155. 26, 27 Our findings indicate that miR-155 targets Rhoa mRNA in resting macrophages, but not in inflammatory macrophages and atherosclerotic lesions, suggesting a switch of the miR-155 effect on RhoA activity during macrophage activation. Taken together, miR-155-mediated suppression of Bcl6 inhibited efferocytosis via increased RhoA activity and thereby promoted necrotic core formation and the progression of atherosclerosis.
Our results indicate that miR-155 targets Bcl6 in lesional macrophages from advanced but not early atherosclerotic lesions. miR-155 was substantially upregulated in macrophages during the progression of atherosclerosis and a lower expression level was required to target Csf1r than Bcl6 in vitro. Thus, upregulation of miR-155 expression levels in advanced lesions may be required for the targeting of Bcl6 and the inhibition of efferocytosis ( Figure 6F ). Short-term treatment with modified or native LDL can increase the expression of miR-155 in macrophages. 18, 20 In addition, we found that long-term treatment of macrophages with oxidized LDL, resulting in foam cell formation and overloading with free cholesterol, 36 which can trigger TLR4 activation, 37-41 strongly upregulates miR-155 expression levels. Of note, TLR4 signaling induces miR-155 expression via activation of inflammatory transcription factors, such as NF-κB (nuclear factor of kappa light polypeptide gene enhancer in B cells 1), AP-1 (activator protein 1), and ETS-2 (E26 avian leukemia oncogene 2). 19, [42] [43] [44] [45] Therefore, accumulation of free cholesterol in foam cells impairs phagocytosis presumably by cholesterolinduced upregulation of miR-155 expression and the suppression of Bcl6. 46, 47 In conclusion, the data in this study demonstrate that miR-155 protects from early, but promotes advanced atherosclerosis. These opposite roles of miR-155 are attributable to the inhibition of macrophage proliferation by suppressing Csf1r in early stages and decreased efferocytosis by targeting Bcl6 in advanced atherosclerosis ( Figure 6F ), highlighting the context-dependent roles of this miRNA. These findings indicate that targeting the interaction between miR-155 and Bcl6 may be a promising approach to prevent the progression of atherosclerosis.
